Walled Lake Planning & Wealth Management LLC Acquires 45,885 Shares of Sanofi $SNY

Walled Lake Planning & Wealth Management LLC acquired a new position in Sanofi (NASDAQ:SNY) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 45,885 shares of the company’s stock, valued at approximately $1,892,000.

A number of other large investors have also recently made changes to their positions in SNY. Western Wealth Management LLC purchased a new position in Sanofi in the first quarter worth about $29,000. Leonteq Securities AG raised its position in Sanofi by 95.8% during the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock valued at $29,000 after purchasing an additional 297 shares during the period. Root Financial Partners LLC bought a new stake in shares of Sanofi in the 3rd quarter valued at approximately $27,000. Whipplewood Advisors LLC lifted its stake in shares of Sanofi by 2,086.1% in the 1st quarter. Whipplewood Advisors LLC now owns 787 shares of the company’s stock valued at $38,000 after purchasing an additional 751 shares during the last quarter. Finally, Montag A & Associates Inc. boosted its holdings in shares of Sanofi by 121.7% in the 1st quarter. Montag A & Associates Inc. now owns 898 shares of the company’s stock worth $43,000 after purchasing an additional 493 shares during the period. 14.03% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. Sanford C. Bernstein reissued a “buy” rating on shares of Sanofi in a research report on Monday, August 3rd. DZ Bank reissued a “buy” rating on shares of Sanofi in a research note on Friday, July 31st. UBS Group reiterated a “neutral” rating on shares of Sanofi in a report on Thursday, September 17th. Wall Street Zen downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Finally, HSBC restated a “buy” rating on shares of Sanofi in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Sanofi currently has an average rating of “Hold” and a consensus target price of $49.50.

Sanofi Stock Performance

Shares of NASDAQ:SNY opened at $44.34 on Monday. The company has a market capitalization of $107.50 billion, a PE ratio of 21.95, a P/E/G ratio of 1.37 and a beta of 0.31. The business’s fifty day simple moving average is $42.21 and its 200-day simple moving average is $44.35. Sanofi has a 12-month low of $39.07 and a 12-month high of $52.68. The company has a current ratio of 0.99, a quick ratio of 0.64 and a debt-to-equity ratio of 0.21.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Friday, October 30th. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.56 by $0.48. The business had revenue of $17.25 billion for the quarter, compared to analyst estimates of $14.30 billion. Sanofi had a net margin of 8.70% and a return on equity of 15.24%. The business’s revenue for the quarter was up 16.2% on a year-over-year basis. During the same period in the previous year, the company earned $2.91 earnings per share. As a group, equities research analysts predict that Sanofi will post 5.00 earnings per share for the current fiscal year.

Sanofi Profile

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases.